At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.

• Conference Overview
• Sarah Emond – ICER
• John O’Brien – National Pharmaceutical Council
• Annette Powers – Bristol Myers Squibb
• Ray Pressburger – Accenture

• Stuart Altman – Power, Politics and Universal Health Care
• PBMs
• 340B Program
• Copay Maximizers
• Net Price
• Lilly Direct
• Indolent Disease, PFS
• Concomitant Drug
• HIV & AZT
• Orphan Drugs
• Calquence vs Imbruvica
• Value-Based Contracts
• Outcome-Based Contracts
• Disruptive PBMs
• CostPlus Drugs
• Fair Access 2024
• Drug Rebates
• Drug Carve-Outs
• Dynamic Pricing
• Accelerated Approvals
• ICER Assessment

Questions? Email [email protected].